News

Among patients with symptomatic Waldenström macroglobulinemia, the very good partial response rate with zanubrutinib was 36.3% vs 25.3% with ibrutinib.

At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.

Tetyana Furmanets, CRNP, MSN, discusses the tools she uses to help patients navigate myeloproliferative neoplasm symptom management.

Oncology nurses can help patients with metastatic lung cancer find meaning in their experiences and potentially help them cope more effectively with their diagnosis.

Experts with the Society for Integrative Oncology and the American Society of Clinical Oncology recommend mindfulness-based interventions to help patients with cancer manage anxiety and depression symptoms.

As we continue to slowly recover from the trauma of the COVID-19 pandemic, we are facing a new problem: chemotherapy shortages.

The FDA has granted ivosidenib priority review designation based on data from a phase 1 trial.

At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.

FoundationOne CDx is a next-generation sequencing–based in vitro diagnostic device developed to detect substitutions, insertion, and deletion alterations using 1 tissue sample.

Jennifer Cargile, MEd, CCC-SLP, shares some signs and symptoms of cancer-related cognitive impairment that the oncology nurse should be looking out for.

ASCO has updated its recommendations for systemic therapies in melanoma.

Florida Cancer Specialists & Research Institute has experts who administer the latest and most advanced treatments for cancer available within the communities where their patients live.

Oncology nurses across the country are spearheading initiatives to improve education, attitudes, and access surrounding palliative care.

Circulating tumor DNA analysis is playing an increasingly important role in colorectal cancer treatment decision-making.

The median disease-free survival with GVAX vaccine plus low-dose cyclophosphamide; GVAX plus cyclophosphamide and nivolumab; and GVAX plus cyclophosphamide, nivolumab, and urelumab, was 13.90 months, 26.1 months, and 31.6 months, respectively.

Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC; and William Dale, MD, PD, discuss the new ASCO geriatric assessment guidelines and what they mean for nurses.

The FDA has approved a liver-directed therapy to treat metastatic uveal melanoma with hepatic metastases.

The FDA has granted accelerated approval to elranatamab-bcmm to treat adults with relapsed or refractory multiple myeloma who have already undergone 4 prior lines of treatment.

The FDA has issued a complete response letter to the new drug application for avasopasem manganese to manage oral mucositis in patients with locally advanced head and neck cancer undergoing radiation.

Two patients experienced 18% and 20% reductions in tumor size following treatment with camsirubicin.

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma achieved antitumor responses with pembrolizumab.

The FDA has approved niraparib and abiraterone acetate to treat patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.

The FDA has approved the therascreen PDGFRA kit to identify patients with gastrointestinal stromal tumors who may benefit from treatment with avapritinib.

Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.

Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.

Talquetamab has received accelerated approval for patients with relapsed or refractory multiple myeloma.

The FDA has granted regular approval to pralsetinib as a treatment for adults with metastatic RET fusion-positive non-small cell lung cancer.

There is room to improve drug adherence, patient education, and adverse event (AE) management for interstitial lung disease and cardiac AEs, according to Patricia Jakel, RN, MN, AOCN.

Relacorilant in combination with nab-paclitaxel did not meet the statistical significance threshold for progression-free survival vs nab-paclitaxel alone.